Literature DB >> 1382014

Drug treatment of the irritable bowel syndrome.

P L Pattee1, W G Thompson.   

Abstract

Irritable bowel syndrome (IBS) is defined as a functional bowel disorder in which abdominal pain is associated with defecation or a change in bowel habit, and with features of disordered defecation and distension. The irritable bowel syndrome occurs in 10 to 20% of people worldwide and is very commonly encountered in clinical practice. This has encouraged the pharmaceutical industry to search for effective drug therapy. So far, a universally effective agent has not been found, and since this is a chronic, benign disorder, beginning in youth, long term drug use should be avoided. Nevertheless, if a specific IBS symptom, such as constipation or abdominal pain dominates, a specific drug may be helpful. However, tests and treatment should be minimised or even avoided in order to do no harm. A largely nonpharmaceutical approach to IBS should be taken. This approach employs drugs sparingly and then only targeted at specific and resistant symptoms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382014     DOI: 10.2165/00003495-199244020-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  40 in total

Review 1.  Are anticholinergics of use in the irritable colon syndrome?

Authors:  K J Ivey
Journal:  Gastroenterology       Date:  1975-05       Impact factor: 22.682

2.  Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study.

Authors:  M R Lucey; M L Clark; J Lowndes; A M Dawson
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

3.  Mebeverine, an effective agent in the irritable colon syndrome.

Authors:  P Baume
Journal:  Aust N Z J Med       Date:  1972-02

Review 4.  Colonic myoelectric activity in the irritable bowel syndrome.

Authors:  W J Snape; G M Carlson; S Cohen
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

5.  Irritable bowel syndrome.

Authors:  B L Mendis; B C Wijesiriwardena; M H Sheriff; K Dharmadasa
Journal:  Ceylon Med J       Date:  1982-12

6.  Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome.

Authors:  J Ritchie
Journal:  Gut       Date:  1973-02       Impact factor: 23.059

7.  Reduction of colonic motility by intravenous nicardipine in irritable bowel syndrome.

Authors:  A Prior; S R Harris; P J Whorwell
Journal:  Gut       Date:  1987-12       Impact factor: 23.059

8.  Functional bowel disorders in apparently healthy people.

Authors:  W G Thompson; K W Heaton
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

9.  Wheat fibre and irritable bowel syndrome. A controlled trial.

Authors:  A P Manning; K W Heaton; R F Harvey
Journal:  Lancet       Date:  1977-08-27       Impact factor: 79.321

10.  Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial.

Authors:  M H Ornstein; E R Littlewood; I M Baird; J Fowler; W R North; A G Cox
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-25
View more
  3 in total

Review 1.  Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease.

Authors:  Akira Andoh; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

2.  Menthol-beta-D-glucuronide: a potential prodrug for treatment of the irritable bowel syndrome.

Authors:  H W Nolen; D R Friend
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

3.  Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.

Authors:  M Dapoigny; J L Abitbol; B Fraitag
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.